These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32680610)

  • 41. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prenatal exposure to methadone and buprenorphine: a review of the potential effects on cognitive development.
    Konijnenberg C; Melinder A
    Child Neuropsychol; 2011; 17(5):495-519. PubMed ID: 21480011
    [TBL] [Abstract][Full Text] [Related]  

  • 43. President's message: Will COVID-19 have a lasting impact on opioid treatment program regulations?
    Kmiec J
    J Addict Dis; 2020; 38(3):239-240. PubMed ID: 32718223
    [No Abstract]   [Full Text] [Related]  

  • 44. A Community Partnership to Improve Access to Buprenorphine in a Homeless Population.
    Leo P; Gastala N; Fleurimont J; Messmer S; Maes P; Richardson J; Neeb C; Stackhouse N; Koruba S; Watson DP
    Ann Fam Med; 2021; 19(1):85. PubMed ID: 33431401
    [No Abstract]   [Full Text] [Related]  

  • 45. Medication-Based Treatment to Address Opioid Use Disorder.
    Leshner AI; Dzau VJ
    JAMA; 2019 Jun; 321(21):2071-2072. PubMed ID: 31046072
    [No Abstract]   [Full Text] [Related]  

  • 46. [Analgesic management of acute pain in patients receiving methadone or buprenorphine].
    Zinck L; Sonne NM; Madsen SL; Nikolajsen L
    Ugeskr Laeger; 2015 Mar; 177(10):. PubMed ID: 25749118
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Kamini, a little recognised source of illicit opioid: A case series of 12 patients.
    Khan T; Ariyawansa P; Quinn J; Hayllar J
    Drug Alcohol Rev; 2022 Sep; 41(6):1404-1407. PubMed ID: 35555819
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
    Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
    Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Abstinence orientation and treatment practice: an analysis of German settings providing opioid maintenance therapy.
    Trautmann S; Wittchen HU
    Subst Use Misuse; 2012 Jan; 47(1):22-30. PubMed ID: 22060728
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potential for Precision Medicine in Methadone Treatment of Opioid Use Disorder.
    Saxon AJ
    J Addict Med; 2020; 14(5):362-363. PubMed ID: 32058338
    [No Abstract]   [Full Text] [Related]  

  • 51. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
    Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
    Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Buprenorphine: reflections of an addictions psychiatrist.
    Selzer J
    J Clin Psychiatry; 2006 Sep; 67(9):1466-7. PubMed ID: 17017836
    [No Abstract]   [Full Text] [Related]  

  • 53. Medical specialty of buprenorphine prescribers for pregnant women with opioid use disorder.
    Hollander MAG; Jarlenski MP; Donohue JM; Cole ES; Kelley D; Krans EE
    Am J Obstet Gynecol; 2019 May; 220(5):502-503. PubMed ID: 30703340
    [No Abstract]   [Full Text] [Related]  

  • 54. Access to treatment for opioid dependence in rural America: challenges and future directions.
    Sigmon SC
    JAMA Psychiatry; 2014 Apr; 71(4):359-60. PubMed ID: 24500040
    [No Abstract]   [Full Text] [Related]  

  • 55. A truly patient-centred evaluation of opioid agonist treatment.
    Trujols J; Vicent-Gil M; Duran-Sindreu S; Portella MJ
    Lancet Psychiatry; 2023 Aug; 10(8):583. PubMed ID: 37479338
    [No Abstract]   [Full Text] [Related]  

  • 56. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Buprenorphine and methadone for opioid addiction during pregnancy.
    Mozurkewich EL; Rayburn WF
    Obstet Gynecol Clin North Am; 2014 Jun; 41(2):241-53. PubMed ID: 24845488
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.
    Tran TH; Griffin BL; Stone RH; Vest KM; Todd TJ
    Pharmacotherapy; 2017 Jul; 37(7):824-839. PubMed ID: 28543191
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Factors associated with buprenorphine versus methadone use in pregnancy.
    Krans EE; Bogen D; Richardson G; Park SY; Dunn SL; Day N
    Subst Abus; 2016; 37(4):550-557. PubMed ID: 26914546
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment.
    Madden A; Lea T; Bath N; Winstock AR
    Drug Alcohol Rev; 2008 Nov; 27(6):671-8. PubMed ID: 19378450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.